Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists
Open Access
- 8 October 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1310
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play an important role in the treatment of type 2 diabetes (T2D) and obesity. The relationship between efficacy and dosing regimen has been studied extensively for this class of molecules. However, a comprehensive analysis of the translation of in vitro data to in vivo efficacious exposure is still lacking. Methods: We collected clinical pharmacokinetics for five approved GLP-1RAs to enable the simulation of exposure profiles and compared published clinical efficacy endpoints (HbA1c and body weight) with in-house in vitro potency values generated in different cell-based assays. Additionally, we investigated the correlation with target coverage, expressed as a ratio between the steady state drug exposure and unbound potency, body weight, or HbA1c reduction in patients with T2D. Results: We found that the best correlation with in vivo efficacy was seen for in vitro potency data generated in cellular assays performed in the absence of any serum albumin or using ovalbumin. Residual variability was larger using in vitro potency data generated in endogenous cell lines or in the presence of human serum albumin. For the human receptor assay with no albumin, exposures above 100-fold in vitro EC50 resulted in >1.5% point HbA1c reduction, while a 5% BW reduction was related to approximately 3× higher exposures. A similar relationship was seen in the ovalbumin assay. Conclusions: Overall, the relationship established for in vitro potency and in vivo efficacy will help to increase confidence in human dose prediction and trial design for new GLP-1RAs in the discovery and early clinical phases.Keywords
Funding Information
- AstraZeneca AB
- AstraZeneca plc
This publication has 41 references indexed in Scilit:
- Quantification of the effect of GLP‐1R agonists on body weight using in vitro efficacy information: An extension of the Hall body composition modelCPT: Pharmacometrics & Systems Pharmacology, 2024
- A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetesReviews in Endocrine and Metabolic Disorders, 2022
- A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonistCPT: Pharmacometrics & Systems Pharmacology, 2021
- Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology TrialsClinical Pharmacokinetics, 2021
- Does In Vitro Potency Predict Clinically Efficacious Concentrations?Clinical Pharmacology & Therapeutics, 2020
- Population Pharmacokinetics of Semaglutide for Type 2 DiabetesDiabetes Therapy, 2019
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptMolecular Metabolism, 2018
- A Model‐Based Meta‐Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic DosesClinical Pharmacology & Therapeutics, 2018
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical TrialsClinical Pharmacokinetics, 2015
- Dulaglutide: First Global ApprovalDrugs, 2014